8-K: Omeros Secures $2.1B Novo Nordisk Deal, Narsoplimab Nears FDA Decision

Omeros Corporation announced third quarter 2025 financial results, a significant licensing agreement with Novo Nordisk for zaltenibart, and updates on its narsoplimab regulatory review.

Summary

• Net loss for Q3 2025 was $30.9 million ($0.47 per share), an improvement from $32.2 million ($0.56 per share) in Q3 2024.
• For the nine months ended September 30, 2025, net loss was $89.8 million ($1.47 per share), down from $125.5 million ($2.15 per share) in the prior year period.
• Non-GAAP adjusted net loss for Q3 2025 was $22.1 million ($0.34 per share) and $89.1 million ($1.46 per share) for the nine months.
• Cash and short-term investments totaled $36.1 million as of September 30, 2025.
• Omeros entered into an Asset Purchase and License Agreement (APLA) with Novo Nordisk Health Care AG for zaltenibart (OMS906), a MASP-3 inhibitor.
• The Novo Nordisk deal includes an upfront cash payment of $240 million upon closing, up to $510 million in near-term and development/approval milestones, up to $1.3 billion in sales-based milestones, and tiered royalties on global net sales (high single-digit to high-teens).
• The upfront payment and existing cash are expected to fund repayment of $67.1 million in term loan principal, $17.1 million in 2026 convertible notes, and provide over 12 months of post-closing operations.
• The FDA extended the PDUFA date for narsoplimab's Biologics License Application (BLA) for TA-TMA to December 26, 2025, following an information request.
• The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for narsoplimab in TA-TMA, with an opinion expected in mid-2026.
• Cash burn during Q3 2025, excluding financing proceeds, was $22.0 million.
• OMIDRIA royalties were $9.2 million in Q3 2025, slightly down from $9.3 million in Q3 2024.
• Total operating expenses decreased by $9.0 million to $26.4 million in Q3 2025, primarily due to a temporary pause in spending to prioritize narsoplimab launch.
• Net loss from discontinued operations was $9.7 million in Q3 2025, compared to net income of $4.9 million in Q3 2024, mainly due to a non-cash remeasurement of the OMIDRIA contract royalty asset.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the transformative licensing deal with Novo Nordisk, which provides substantial non-dilutive capital and validates a key pipeline asset. Combined with the nearing FDA decision for narsoplimab and progress across other programs, these strategic advancements outweigh the ongoing net losses and minor regulatory delays.

Positives

• Secured a transformative Asset Purchase and License Agreement with Novo Nordisk for zaltenibart, potentially worth up to $2.1 billion plus tiered royalties.
• The upfront payment from Novo Nordisk is expected to provide sufficient capital to repay all outstanding senior secured credit agreement obligations ($67.1 million), repay 2026 convertible notes ($17.1 million), and fund over 12 months of post-closing operations.
• Net loss decreased year-over-year for both the three and nine months ended September 30, 2025.
• Narsoplimab's BLA resubmission for TA-TMA is nearing an FDA decision with a PDUFA date of December 26, 2025, and all requested analyses have provided statistically significant support of benefit.
• The EMA has validated the MAA for narsoplimab in TA-TMA, initiating the formal review process.
• The U.S. commercial organization for narsoplimab is assembled and launch-ready, with encouraging pre-approval engagements.
• Established a national ICD-10 diagnostic code and a CPT procedural code specifically for narsoplimab, positioning it as the only reimbursable TA-TMA treatment upon approval.
• Expectation to receive a New Technology Add-On Payment (NTAP) under Medicare for narsoplimab.
• Two peer-reviewed manuscripts detailing narsoplimab's safety and survival benefits in high-risk TA-TMA patients were published in premier journals.
• Preclinical studies for OMS527 (PDE7 inhibitor for cocaine use disorder) were completed with no safety findings, supporting planned human studies.
• OncotoX-AML program shows broad application across AML regardless of genetic mutation and superior efficacy to standard of care in animal and in vitro studies, with encouraging safety results in non-human primates.
• The Targeted Complement Activating Therapy (T-CAT) platform continues to amass animal data for multidrug-resistant organisms.

Negatives

• The company continues to report a net loss, with $30.9 million in Q3 2025 and $89.8 million for the nine months.
• Cash and short-term investments were $36.1 million at September 30, 2025, indicating a reliance on the upcoming Novo Nordisk upfront payment for financial stability.
• FDA requested additional preclinical information for OMS527, delaying the initiation of the clinical in-patient study in cocaine users to the second half of 2026.
• Net loss from discontinued operations was $9.7 million in Q3 2025, a decrease from net income in the prior year, primarily due to a non-cash remeasurement.

Risks

• The closing of the Asset Purchase and License Agreement with Novo Nordisk is subject to the satisfaction or waiver of certain customary closing conditions.
• There is no guarantee that the FDA or EMA will approve narsoplimab for TA-TMA, and regulatory conclusions could be unfavorable or unexpected.
• The company may be unable to respond satisfactorily to information requests during regulatory review of the narsoplimab BLA or MAA.
• Potential differences between diagnostic criteria used in the pivotal trial and external registries, and whether FDA and EMA deem the registry sufficiently representative of TA-TMA patients.
• Challenges associated with the manufacture or supply of products to support clinical trials, regulatory inspections, and/or commercial sale following any marketing approval.
• Changes in reimbursement and payment policies by government and commercial payers or the application of such policies could impact commercial success.
• Intellectual property claims, competitive developments, and litigation could adversely affect the company.
• The company's financial condition and results of operations, including its ability to raise additional capital for operations or complete other transactions on favorable terms or at all, pose ongoing risks.

Future Outlook

The company anticipates a potentially transformative period ahead, driven by the expected closing of the Novo Nordisk transaction, the fast-approaching FDA decision on narsoplimab for TA-TMA, and the planned commercial launch of narsoplimab. These events are expected to provide financial strength and operational flexibility to accelerate development across its pipeline programs, including OMS1029, OMS527, T-CAT, and the oncology therapeutic platform. The in-patient clinical study for OMS527 is targeted for the second half of 2026, and the OncotoX-AML therapeutic is estimated to enter the clinic in 18-24 months.

Management Comments

• "Our team delivered a series of accomplishments in the third quarter that I believe position Omeros for a potentially transformative period ahead."
• "The crucial above-market financing completed in July, the development of the Novo Nordisk transaction expected to close before year-end, and FDA’s fast-approaching decision on approval for narsoplimab in TA-TMA — each of these strategic components was set in motion and consummated or greatly solidified during the quarter."
• "Together, they could well provide the financial strength and operational flexibility to accelerate significantly the development across our first-in-class pipeline programs, including our long-acting MASP-2 inhibitor OMS1029, our PDE7 inhibitor OMS527 for the treatment of addictions and compulsions, our T-CAT program targeting multidrug-resistant pathogens, and our oncology therapeutic platform."
• "Success in any one of these programs could deliver significant clinical benefit to our patients and substantial value to our shareholders."
• "In the near term, we look forward to the closing of the Novo Nordisk transaction and, importantly, to FDA’s decision and the planned commercial launch of narsoplimab."

Industry Context

The biopharmaceutical industry continues to see significant licensing and partnership deals, especially for promising clinical-stage assets. Omeros's agreement with Novo Nordisk for zaltenibart (MASP-3 inhibitor) highlights the increasing value placed on novel mechanisms in complement-mediated diseases, particularly by large pharmaceutical companies seeking to expand their portfolios. The progress of narsoplimab (MASP-2 inhibitor) in TA-TMA, a rare and severe condition, positions Omeros to address a critical unmet medical need, aligning with the industry's focus on orphan indications. The establishment of specific reimbursement codes for narsoplimab also reflects strategic planning for market access in the complex U.S. healthcare landscape.

Comparison to Industry Standards

• The licensing deal with Novo Nordisk, a global leader in pharmaceuticals, for zaltenibart (OMS906) with potential payments up to $2.1 billion plus royalties, is a strong validation of Omeros's MASP-3 inhibitor program and its potential in the complement pathway space. This type of large-scale partnership is indicative of high-value assets in the biopharmaceutical industry.
• Narsoplimab's reported survival benefits in high-risk TA-TMA patients, as detailed in peer-reviewed publications like Blood Advances and the American Journal of Hematology, compare favorably against standard of care and other complement agents (e.g., C5 inhibitors, defibrotide). This suggests a potentially superior or differentiated profile in a severe, unmet need indication.
• The assembly of a launch-ready U.S. commercial organization and proactive engagement with payers and transplant centers for narsoplimab aligns with best practices for companies preparing to commercialize a novel therapy in a specialized market, similar to strategies employed by companies like Alexion (now AstraZeneca Rare Disease) for complement inhibitors.

Related Party Transactions

• OMIDRIA royalties of $9.2 million were earned from Rayner Surgical Inc. in Q3 2025. Per agreements with DRI Health Acquisition LP, all U.S.-based royalties through 2031 are remitted from Rayner to DRI through an escrow agent.

Stakeholder Impact

• Shareholders: Potential for significant value creation from the Novo Nordisk licensing deal and narsoplimab approval, offset by recent dilution from equity offerings.
• Patients: Potential for new treatment options for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) with narsoplimab, and future therapies for PNH, C3 glomerulopathy, cocaine use disorder, AML, and multidrug-resistant pathogens.
• Employees: Increased operational flexibility and potential for accelerated pipeline development, particularly for the commercial team preparing for narsoplimab launch.
• Creditors: Improved financial position and clear path to debt repayment with the proceeds from the Novo Nordisk transaction.

Next Steps

• Closing of the Asset Purchase and License Agreement with Novo Nordisk, expected in the fourth quarter of 2025.
• FDA decision on the Biologics License Application (BLA) for narsoplimab in TA-TMA by the extended PDUFA date of December 26, 2025.
• Planned commercial launch of narsoplimab (YARTEMLEA) in the U.S. following anticipated FDA approval.
• Repayment of all outstanding obligations under the senior secured credit agreement ($67.1 million) upon closing of the Novo Nordisk transaction.
• Repayment of the $17.1 million remaining principal balance of 2026 convertible notes at or prior to maturity in February 2026.
• European Medicines Agency (EMA) Committee for Medicinal Products for Human Use to render its opinion on narsoplimab's MAA in mid-2026.
• Initiation of an in-patient, placebo-controlled clinical study evaluating OMS527 in adult cocaine users, targeted for the second half of 2026.
• Continued IND-enabling work for the OncotoX biologics program, with an estimated entry into the clinic for OncotoX-AML in 18-24 months.
• Further development of the Targeted Complement Activating Therapy (T-CAT) platform.

Key Dates

Recommendation

The announcement of the substantial licensing agreement with Novo Nordisk for zaltenibart, providing a significant upfront payment and potential milestones, fundamentally de-risks Omeros's financial position and validates its drug discovery platform. This capital infusion is critical for debt repayment and funding operations, reducing immediate capital raise concerns. Coupled with the imminent FDA decision for narsoplimab in TA-TMA, which has shown strong clinical data and is poised for commercial launch, the company is at an inflection point. While still reporting losses, the strategic moves position Omeros for significant long-term growth and value creation, making it an attractive 'buy' for investors with a medium to long-term horizon.

Keywords

Omeros Corporation, OMER, Financial Results, Q3 2025, Novo Nordisk, Zaltenibart, OMS906, MASP-3 inhibitor, Narsoplimab, YARTEMLEA, TA-TMA, FDA Approval, PDUFA, EMA Review, Biopharmaceutical, Clinical-stage, Complement-mediated diseases, Oncology, Addiction, Pipeline, Licensing Agreement, Biologics License Application, Marketing Authorization Application, Cash Position, Net Loss, OMIDRIA Royalties, Capital Raise, Drug Development